Company news

Gilead Sciences, Inc. news in 2020

Gilead Sciences, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe

December 15, 2020

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

December 14, 2020

Gilead Sciences to Acquire MYR GmbH

December 9, 2020

Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States

December 8, 2020

Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors

December 7, 2020

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

November 17, 2020

Gilead Sciences Announces Fourth Quarter 2020 Dividend

October 27, 2020

Gilead Sciences Completes Acquisition of Immunomedics, Inc.

October 22, 2020

U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

October 21, 2020

Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans

October 20, 2020

Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020

October 13, 2020

Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir)

October 7, 2020

Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020

October 4, 2020

Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States

September 30, 2020

Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis

September 24, 2020

Calls in 2020

Decks in 2020